Alnylam announces preliminary* fourth quarter and full year 2024 global net product revenues and provides 2025 combined net product revenue guidance and pipeline goals

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced its preliminary* fourth quarter and full year 2024 global net product revenues for onpattro, amvuttra, givlaari, and oxlumo. in addition, the company provided 2025 net product revenue, non-gaap operating income profitability, and pipeline goals guidance. “alnylam's commercial and clinical achievements in 2024 position us very well for another transformative yea.
ALNY Ratings Summary
ALNY Quant Ranking